期刊
DIALOGUES IN CLINICAL NEUROSCIENCE
卷 24, 期 1, 页码 10-69出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/19585969.2022.2134739
关键词
Compulsive sexual behaviour disorder; hypersexuality; addictive behaviours; compulsive behaviours; sexual addiction; paraphilias; chemsex
The study aims to evaluate the role of pharmacological agents in the treatment of patients with CSBD. The results indicate that psychoeducation and psychotherapy are the first-choice treatments, while selective serotonin reuptake inhibitors and naltrexone are the most relevant pharmacological treatments. Hormonal agents may be indicated for CSBD with comorbid paraphilic disorders.
Objectives: The current guidelines aim to evaluate the role of pharmacological agents in the treatment of patients with compulsive sexual behaviour disorder (CSBD). They are intended for use in clinical practice by clinicians who treat patients with CSBD. Methods: An extensive literature search was conducted using the English-language-literature indexed on PubMed and Google Scholar without time limit, supplemented by other sources, including published reviews. Results: Each treatment recommendation was evaluated with respect to the strength of evidence for its efficacy, safety, tolerability, and feasibility. Psychoeducation and psychotherapy are first-choice treatments and should always be conducted. The type of medication recommended depended mainly on the intensity of CSBD and comorbid sexual and psychiatric disorders. There are few randomised controlled trials. Although no medications carry formal indications for CSBD, selective-serotonin-reuptake-inhibitors and naltrexone currently constitute the most relevant pharmacological treatments for the treatment of CSBD. In cases of CSBD with comorbid paraphilic disorders, hormonal agents may be indicated, and one should refer to previously published guidelines on the treatment of adults with paraphilic disorders. Specific recommendations are also proposed in case of chemsex behaviour associated with CSBD. Conclusions: An algorithm is proposed with different levels of treatment for different categories of patients with CSBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据